Brought to you by 
U3 Pharma completes €13.25mm second round
06 Oct 2003
Executive Summary
U3 Pharma AG (cellular signal transduction systems) completed a second-round private placement grossing €13.25mm ($14.35mm). New investors were Atlas Venture and LCF Rothschild Venture Partners (which co-led the financing) and BioMedical Sciences Investment Fund. Returning backers were Alta Partners (which made a significant investment), BioM, and Medicis Venture Management, as well as private investors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
U3 Pharma completes €13.25mm second round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice